Gilead, Teva Agree to End Patent Feud

Biotech firm Gilead Sciences (NASDAQ: GILD  ) and pharmaceutical company Teva Pharmacaeutical (NYSE: TEVA  ) have agreed to settle an ongoing lawsuit regarding Gilead's patents of HIV and hepatitis B medication Viread.

A trial had been scheduled to begin Wednesday, with the settlement on Tuesday avoiding that if the agreement between the two is finalized. The agreement will allow Teva to market a generic version of Viread beginning in December 2017.

Gilead first sued Teva in 2008 over alleged infringement concerning four of its patents, doing so once again in 2010 in what became a lengthy legal fight. Viread pulled in $849 million in sales last year for Gilead, making the case an important one for its revenue.

Gilead President and Chief Operating Officer Dr. John Milligan commented on the agreement in his company's release, saying, "This settlement ... removes some uncertainty and minimizes further distraction and investment of human and financial resources associated with this litigation."

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2269735, ~/Articles/ArticleHandler.aspx, 12/18/2014 7:50:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement